Variable | Training group | Validated group | P value |
---|---|---|---|
Number | 60 | 218 | Â |
Sex, male, n (%) | 32 (53.3) | 127 (58.3) | 0.556 |
Age, median (range), years | 48.00 [37.75, 53.00] | 52.50 [39.00, 63.00] | 0.001 |
WBC, median (IQR), × 109/L | 19.05 [7.87, 40.23] | 14.20 [3.70, 60.02] | 0.746 |
HB, median (IQR), g/L | 84.00 [69.00, 97.00] | 84.50 [67.00, 103.75] | 0.760 |
PLT, median (IQR), × 109/L | 40.00 [27.00, 65.00] | 48.00 [25.25, 85.50] | 0.225 |
BM blast, median (IQR), % | 63.00 [44.00, 81.75] | 68.25 [43.25, 83.38] | 0.367 |
FAB classification, n (%) | Â | Â | 0.674 |
 M0 | 5 (8.3) | 26 (11.9) |  |
 M1 | 7 (11.7) | 24 (11.0) |  |
 M2 | 26 (43.3) | 103 (47.2) |  |
 M4 | 4 (6.7) | 9 (4.1) |  |
 M5 | 17 (28.3) | 55 (25.2) |  |
 M6 | 1 (1.7) | 1 (0.5) |  |
Gene mutations, n (%) | |||
 FLT3-ITD | 14 (23.3) | 45 (20.6) | 0.722 |
 NPM1 | 17 (28.3) | 54 (25.8) | 0.740 |
 CEBPADM | 4 (6.7) | 34 (16.8) | 0.060 |
 DNMT3A | 8 (13.3) | 28 (13.9) | 1.000 |
 IDH1 | 12 (20.0) | 32 (16.0) | 0.556 |
 IDH2 | 11 (18.3) | 24 (12.6) | 0.288 |
ENL favorable group | 17 (28.3) | 59 (27.1) | 0.871 |